Postoperative radiotherapy for localized prostate cancer: Clinical significance of nadir prostate-specific antigen value within 12 months

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4605-4613

  Ogawa, Kazuhiko ^a   Nakamura, Katsumasa ^b   Sasaki, Tomonari ^c   Onishi, Hiroshi ^d   Koizumi, Masahiko ^e   Araya, Masayuki ^d   Mukumoto, Nobutaka ^e   Mitsumori, Michihide ^f   Teshima, Teruki ^e  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^d UNIVERSITY OF YAMANASHI   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f KYOTO UNIVERSITY   (Japan)

Author keywords

Biochemical failure; NPSA12; Prognostic factor; Prostate cancer; Radiotherapy; Surgery

Indexed keywords

ANTIANDROGEN; ESTRAMUSTINE; ESTROGEN; FLUOROURACIL; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; DISTANT METASTASIS; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; URETER OBSTRUCTION; URETER STRICTURE; URINE INCONTINENCE;

AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 75149148108     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, Bosset JF, Kurth KH, Schröder FH and Collette L; EORTC 22911: Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25: 4178-4186, 2007.
2. Kupelian P, Katcher J, Levin H, Zippe C and Klein E: Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48: 249-260, 1996.
3. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP and Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152: 1850-1857, 1994.
4. Catalona WJ and Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 160: 2428-2434, 1998.
5. Walsh PC, Partin AW and Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152: 1831-1836, 1994.
6. Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr, Schellhammer PF, Ohori M, Chodak GW: Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 276: 615-619, 1996.
7. Wheeler TM, Dillioglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, Ohori M and Scardino PT: Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol 29: 856-862, 1998.
8. Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, Slawin K and Scardino PT: Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 174: 903-907, 2005.
9. Numata K, Azuma K, Hashine K and Sumiyoshi Y: Predictor of response to salvage radiotherapy in patients with PSA recurrence after radical prostatectomy: the usefulness of PSA doubling time. Jpn J Clin Oncol 35: 256-259, 2005.
10. Morgan SC, Waldron TS, Eapen L, Mayhew LA, Winquist E, Lukka H and Genitourinary Cancer Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care: Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and metaanalysis. Radiother Oncol 88: 1-9, 2008.
11. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Maréchal JM, Scalliet P, Haustermans K, Piérart M and European Organization for Research and Treatment of Cancer: Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366: 572-578, 2005.
12. Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA and Martinez AA: Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Int J Radiat Oncol Biol Phys 61: 714-724, 2005.
13. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncologyTM. Prostate cancer. V.2. 2009. http://www.nccn.org/professionals/ physician-gls/PDF/prostate.pdf.
14. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E and Crawford ED: Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296: 2329-2335, 2006.
15. Alcantara P, Hanlon A, Buyyounouski MK, Horwitz EM and Pollack A: Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 109: 41-47, 2007.
16. Ray ME, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Zelefsky MJ, Zietman AL and Kuban DA: Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology 68: 1257-1262, 2006.
17. Zietman AL, Tibbs MK, Dallow KC, Smith CT, Althausen AF, Zlotecki RA and Shipley WU: Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol 40: 159-162, 1996.
18. Lee WR, Hanlon AL and Hanks GE: Prostate-specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J Urol 156: 450-453, 1996.
19. Crook JM, Bahadur YA, Bociek RG, Perry GA, Robertson SJ and Esche BA: Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate-specific antigen and nadir prostate-specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer 79: 328-336, 1997.
20. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MI, Zietman AL and Kuban DA: PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 64: 1140-1150, 2006.
21. Hanlon AL, Diratzouian H and Hanks GE: Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53: 297-303, 2002.
22. Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R and Horwitz EM: Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 57: 19-23, 2003.
23. Teshima T and Japanes PCS Working Group: Patterns of care study in Japan: Jpn J Clin Oncol 35: 497-506, 2005.
24. Sasaki T, Nakamura K, Ogawa K, Onishi H, Otani Y, Koizumi M, Shioyama Y, Teshima T and Japanese Patterns of Care Study Working Subgroup of Prostate Cancer: Postoperative radiotherapy for patients with prostate cancer in Japan; Changing trends in national practice between 1996-98 and 1999-2001: Patterns of care study for prostate cancer. Jpn J Clin Oncol 36: 649-654, 2006.
25. Hanks GE, Coia LR and Curry J: Patterns of care studies: past, present and future. Semin Radiat Oncol 7: 97-100, 1997.
26. Owen JB, Sedransk J and Pajak TF: National averages for process and outcome in radiation oncology: Methodology of the patterns of care study. Semin Radiat Oncol 7: 101-107, 1997.
27. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH and Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65: 965-974, 2006.
28. SAS procedure reference, version 6. 1st ed. Tokyo: SAS Institute Iin Japan; 1995.
29. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
30. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
31. Cox DR: Regression models and life tables. J R Stat Soc 34: 187-220, 1972.
32. Cox JD, Stetz J and Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31: 1341-1346, 1995.
33. Cozzarini C, Bolognesi A, Ceresoli GL, Fiorino C, Rossa A, Bertini R, Colombo R, Da Pozzo L, Montorsi F, Roscigno M, Calandrino R, Rigatti P and Villa E: Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. Int J Radiat Oncol Biol Phys 59: 674-683, 2004.
34. Petrovich Z, Lieskovsky G, Langholz B, Jozsef G, Streeter OE Jr and Skinner DG: Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 53: 600-609, 2002.
35. Choo R, Hruby G, Hong J, Hong E, DeBoer G, Danjoux C, Morton G, Klotz L, Bhak E and Flavin A: Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys 52: 674-680, 2002.
36. Macdonald OK, Schild SE, Vora SA, Andrews PE, Ferrigni RG, Novicki DE, Swanson SK and Wong WW: Radiotherapy for men with isolated increase in serum prostate-specific antigen after radical prostatectomy. J Urol 170: 1833-1837, 2003.
37. Anscher MS, Clough R and Dodge R: Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys 48: 369-375, 2000.
38. Ogawa K, Nakamura K, Sasaki T, Onishi H, Koizumi M, Shioyama Y, Araya M, Mukumoto N, Mitsumori M and Teshima T: External beam radiotherapy for clinically localized hormone-refractory prostate cancer: Clinical Significance of Nadir Prostate-Specific Antigen value within 12 Months. Int J Radiat Oncol Biol Phys 74: 759-765, 2009.
39. King CR, Presti JC, Brooks JD, Gill H and Spiotto MT: Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 70: 1472-1477, 2008.
40. Wadasaki K, Kaneyasu Y, Kenjo M, Matsuura K, Murakami Y, Hashimoto Y, Ito K, Kiriu H and Ito A: Treatment results of adjuvant radiotherapy and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Clin Oncol 12: 37-41, 2007.
41. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT and Slawin KM: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291: 1325-1332, 2004.
42. Sasaki T, Nakamura K, Shioyama Y, Ohga S, Toba T, Urashima Y, Yoshitake T, Terashima H, Koga H, Naito S, Noma H, Komatsu K, Yamaguchi A, Hiratsuka Y, Hirano T, Hanada K, Abe M, Fujisawa Y and Honda H: Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer. Anticancer Res 26: 2367-2374, 2006.
43. Schild SE, Wong WW, Grado GL, Halyard MY, Novicki DE, Swanson SK, Larson TR and Ferrigni RG: The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys 34: 535-541, 1996.
44. Morris MM, Dallow KC, Zietman AL, Park J, Althausen A, Heney NM and Shipley WU: Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 38: 731-736, 1997.
45. Valicenti RK, Gomella LG, Ismail M, Strup SE, Mulholland SG, Dicker AP, Petersen RO and Newschaffer CJ: The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 45: 53-58, 1999.